Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child

^aPediatric Nephrology Unit and
^bPediatric Hematology-Oncology Unit, Division of Pediatrics, Department Woman-Mother-Child and
^fDivision of Hematology and Central Hematology Laboratory and
^cServices of Clinical Pathology and
^dClinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland;
^eDepartment of Pediatrics, University Children’s Hospital Zurich and University of Zurich, Zurich, Switzerland; and
^gCancer and Blood Disease Institute, Children’s Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California

Drs Chehade and Rizzi provided patient care, coordinated and supervised data collection, analyzed and interpreted clinical and laboratory data, designed and wrote the manuscript, and critically reviewed the manuscript for important intellectual content; Drs Rotman and Alberio analyzed and interpreted laboratory results and contributed to the writing of the manuscript; Dr Diezi evaluated pharmacologic aspects and contributed to the writing of the manuscript; Drs Cachat, Beck-Popovic, and Albisetti interpreted data and contributed to the writing of the manuscript; Dr Young interpreted data, contributed to the design and writing of the manuscript, and critically reviewed the manuscript for important intellectual content; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.